Recent experience

Recent experience kinase inhibitor Crizotinib with BRAF inhibitors has suggested that a very high level of pathway inhibition is necessary in order to achieve clinical tumor shrinkage. One hypothetical salvage mechanism is through regulated expression of MAP Kinase phosphatases, which might be highly expressed in tumor cells that have constitutive ERK acti vation, but may decrease in expression when the ERK pathway is partially inhibited, thus resulting in little change in the final output of ERK phosphorylation of target genes. Inhibitors,Modulators,Libraries These and other potential mechanisms of resistance will be of interest to pursue in future studies of targeted inhibitors in melanoma. Background The treatment of cancer is constantly evolving towards the integration of ever advancing Inhibitors,Modulators,Libraries knowledge of disease processes and improvements in molecular and computa tional technologies.

Until recently, approaches towards the treatment of cancer have been disease centric and pre dominantly determined on the basis of histological Inhibitors,Modulators,Libraries classi fication. However, the disparate responses of patients to a given agent with the same disease defined through this method of nosology has been attributed to significant molecular heterogeneity within phenotypically defined tu mors, and Inhibitors,Modulators,Libraries demands the inclusion of molecular biomarkers towards the improved classification of cancers. The last 20 years has seen an explosion in both genomic and proteomic technologies, that have assisted in increas ing our understanding of disease heterogeneity and have aggressively driven the focus of both drug discovery and development towards the fundamental molecular drivers of disease.

Advances in molecular and computational technologies now permit the global analysis of the gen ome, epigenome, proteome and metabolome at unprece dented granularity, and provide opportunities Inhibitors,Modulators,Libraries to study disease heterogeneity within an individual and across pop ulations. This revolution in technologies has made the promise of personalized medicine a reality, through selleck chemicals which health care can be customizedtailored for an individual based on information derived from the patient andor their disease. In the sub branch of personalized medi cine often referred to as pharmacogenomics or precision therapeutics, molecular biomarkers are being used with increased frequency to identify agents with predicted efficacy.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>